Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.48 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.48 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.48 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.48 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9130864 | 0.98 | KMT2A (0.66) | KMT2AALDH1A1MEN1L3MBTL1HTT | |
| SCHEMBL3366949 | 0.98 | KMT2A (0.70) | KMT2AALDH1A1MEN1L3MBTL1HTT | |
| Water SCHEMBL3678915 | 0.96 | KMT2A (0.68) | KMT2AALDH1A1MEN1L3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL27410606 | 0.89 | ALOX5 (0.67) | KMT2AALDH1A1ALOX5NPC1RAB9A | |
| SCHEMBL7088866 | 0.87 | FFAR1 (0.65) | KMT2AALDH1A1MEN1L3MBTL1HTT | |
| SCHEMBL8493143 | 0.86 | ALOX5 (0.69) | KMT2AALDH1A1ALOX5NPC1RAB9A | |
| SCHEMBL386559 | 0.85 | ALOX5 (0.77) | KMT2AALOX5HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL6165650 | 0.85 | KMT2A (0.64) | KMT2AALDH1A1MEN1L3MBTL1HTT | |
| SCHEMBL448875 | 0.84 | ALOX5 (0.77) | KMT2AALDH1A1MEN1L3MBTL1HTT | |
| SCHEMBL7073173 | 0.84 | KMT2A (0.54) | KMT2AALDH1A1MEN1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026068-A | EP2 antagonists | 小野药品工业株式会社 | 2022-02-08 | — | — | CN | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| CN-100480249-C | Pyrrolopyridine-2-carboxylic acid amides as glycogen phosphorylase inhibitors | PROSIDION LTD (GB) | 2009-04-22 | — | — | CN | disclosed |
| CN-1826340-A | Pyrrolopyridine-2-carboxylic acid amides as glycogen phosphorylase inhibitors | PROSIDION LTD (GB) | 2006-08-30 | — | — | CN | disclosed |
| US-20060140888-A1 | Whitening agent containing crystalline molecular complex of hydroquinone and surfactant | CIRCLE FOR THE PROMOTION OF SCIENCE AND ENGINEERING, THE (JP) | 2006-06-29 | — | — | US | disclosed |
| EP-1636224-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | Prosidion Limited (GB) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
| EP-1051210-A2 | ENHANCED BIOCOMPATIBILITY COATINGS FOR MEDICAL IMPLANTS | Edwards Lifesciences Corporation (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038547-A2 | ENHANCED BIOCOMPATIBILITY COATINGS FOR MEDICAL IMPLANTS | EDWARDS LIFESCIENCES CORPORATION (US) | 1999-08-05 | — | — | WO | disclosed |
| CN-1142492-A | Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents | PFIZER (US) | 1997-02-12 | — | — | CN | disclosed |
| US-5382492-A | Thermoplastic resin particles, nonpolar liquids and benzyl acetyldimethylammonium chloride | XEROX CORPORATION (US) | 1995-01-17 | — | — | US | disclosed |
| US-4824532-A | Process for the electrochemical synthesis of carboxylic acids | SOCIETE NATIONALE INDUSTRIELLE ET AEROSPATIALE DES POUDRES ET (FR) | 1989-04-25 | — | — | US | disclosed |